RCT: Pembrolizumab vs. chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Overall Survival in KEYNOTE-177: Pembrolizumab vs Chemotherapy in Microsatellite Instability–High or Mismatch Repair–Deficient Metastatic Colorectal Cancer – The ASCO Post